Health & Fitness
Health and Fitness
Health and Fitness 
Fri, January 30, 2009
Thu, January 29, 2009
Fraunhofer USA to use iBioPharma?s Technology for Pandemic Flu Vaccine Research
NEWARK, Del.--([ BUSINESS WIRE ])--iBioPharma, Inc. (OTCBB:IBPM) partner Fraunhofer USA Center for Molecular Biotechnology (CMB) announced today that it has received an $8.7 million grant from the Bill & Melinda Gates Foundation for clinical development of an avian influenza vaccine based upon iBioPharma's proprietary technology. The new funding will support CMB's continued work to develop vaccines against avian influenza and advance promising candidates into clinical trials. A not-for-profit research organization, CMB uses iBioPharma's proprietary transient plant-based technology to develop and manufacture novel vaccines and therapeutics.
"It is essential that new vaccines reach the people who need them most," said Doug Holtzman, Senior Program Officer for the Bill & Melinda Gates Foundation. "Using iBioPharma's innovative technology, CMB's research may help developing countries to respond quickly to outbreaks of influenza and other infectious diseases to significantly limit their impact on vulnerable populations."
iBioPharma has agreed to make its technology available for non-profit global health research, but will retain exclusive commercial rights to the technology and its product applications.
"We are very pleased that the progress made on this project has resulted in continued support for CMB's vital research," said Robert Kay, Chairman and CEO of iBioPharma. "This approach has the potential to produce flu vaccines in substantially less time and, at vastly greater scale, than in egg-based systems."
About iBioPharma, Inc.
iBioPharma (OTCBB:IBPM) is a biopharmaceutical company focused on vaccines and therapeutic antibodies against infectious diseases using its proprietary plant-based technologies. iBioPharma's proprietary technology is designed for speed, scalability and surge capacity to respond to global demands. Further information is available at [ www.ibiopharma.com ].
Statements included in this release related to iBioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.